Walleye Capital’s PTC Therapeutics PTCT Stock Holding History

Walleye Capital’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-800	Closed	-$60.8K	–	4861
2025 Q4	$60.8K	Buy	+800	New	+$58.1K	﹤0.01%	4033
2024 Q2	–	Sell	-600	Closed	-$17.5K	–	5917
2024 Q1	$17.5K	Buy	+600	New	+$16.8K	﹤0.01%	4962
2023 Q2	–	Sell	-1,400	Closed	-$67.8K	–	4779
2023 Q1	$67.8K	Buy	1,400 +1,000	+250%	+$45.7K	﹤0.01%	3095
2022 Q4	$15.3K	Buy	+400	New	+$16.6K	﹤0.01%	2703
2020 Q1	–	Sell	-34,800	Closed	-$1.67M	–	1505
2019 Q4	$1.67M	Sell	34,800 -7,600	-18%	-$323K	0.11%	256
2019 Q3	$1.43M	Buy	42,400 +38,000	+864%	+$1.65M	0.09%	321
2019 Q2	$198K	Sell	4,400 -2,000	-31%	-$79K	0.02%	975
2019 Q1	$241K	Buy	+6,400	New	+$215K	0.04%	689

Other funds holding PTCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Walleye Capital's PTCT Position: Q1 2026 in Review

Walleye Capital sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 18,074 shares — an estimated $1.37M sold.

Walleye Capital first reported a position in PTCT in Q2 2019 and held it in 15 quarters. The position peaked at $4.97M in Q4 2024. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

Walleye Capital reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
Walleye Capital sold 18,074 PTC Therapeutics shares in Q1 2026, an estimated $1.37M.
Walleye Capital first reported a position in PTC Therapeutics in Q2 2019 and held it in 15 quarters.
Walleye Capital's PTC Therapeutics position peaked at $4.97M in Q4 2024.
349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.